The purpose of this study is to compare how two FDA-approved eye drops: netarsudil (Rhopressa) and timolol, protect nerve cells in the eye of adults with open-angle glaucoma. Both medications lower pressure inside the eye, but researchers want to learn if Rhopressa is more effective at slowing down or preventing the loss of retinal ganglion cells. These cells are essential for sight because they carry visual signals from the eye to the brain.
Participants in this study will complete a total of 6 study visits over 12 months:
* Participants will spend 6 months using Rhopressa eye drops and 6 months using Timolol eye drops. The order of the two eye drops will be chosen randomly.
* At scheduled study visits, researchers will examine participants' eyes and measure eye pressure.
* Researchers will take detailed pictures of the back of the eye using a specialized high-resolution camera called adaptive optics optical coherence tomography (AO-OCT).
* Participants will also complete specialized visual field testing to measure eye function.
Researchers will count and track individual nerve cells over time to determine if one medication offers better protection against cell loss than the other.

Start Date01 Oct 2026

Sponsor / Collaborator

Indiana University

[+1]

NCT07588152

/ RecruitingPhase 4IIT

Adaptive Optics Gonioscopy In Vivo Imaging of the Effects of Rhopressa on the Trabecular Meshwork in Patients With Ocular Hypertension or Glaucoma

This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.

Start Date05 Jun 2026

Sponsor / Collaborator

Indiana University

[+1]

KCT0012553

/ RecruitingNot ApplicableIIT

A prospective, multicenter, open-label, single-arm, Real World Evidence study with Masked IOP Assessment to evaluate efficacy(Effectiveness) of Netarsudil 0.02% ophthalmic solution as an Add-On therapy in patients with Normal-Tension Glaucoma receiving latanoprost 0.005%

Start Date27 Jan 2026

Sponsor / Collaborator

Seoul National University Bundang Hospital

100 Clinical Results associated with Netarsudil Mesylate

100 Translational Medicine associated with Netarsudil Mesylate

100 Patents (Medical) associated with Netarsudil Mesylate

205

Literatures (Medical) associated with Netarsudil Mesylate

31 Dec 2026·DRUG DELIVERY

Preparation of a new fixed-combination carteolol-netarsudil ophthalmic solution via one-pot pH-adjusting solubilization strategy for glaucoma treatment

Article

Author: Zhang, Tianhong ; Ran, Xiaohua ; Wang, Tao ; Zhao, Chunyang ; Jiao, Dian ; Sun, Jin ; Lu, Tu ; Li, Yanxin ; Ma, Xiaoli ; Jiang, Qikun ; Liu, He-Nan ; Liu, Yanhua

Currently, the commercial fixed-combination of two agents is facing several clinical challenges, including suboptimal intraocular pressure (IOP) reduction, which requires multiple daily administrations, compromised bioavailability due to rapid tear film clearance and nasolacrimal drainage, and preservative-induced ocular surface toxicity. To address these limitations, we intend to develop a novel preservative-free, long-acting fixed-combination formulation of carteolol hydrochloride and netarsudil dimesylate. This once-daily formulation demonstrates enhanced therapeutic potential through optimized physicochemical stability and extended ocular residence time in theory. However, commercialized netarsudil dimesylate is precipitated when the pH of the solution is above 5.4 or when carteolol hydrochloride is mixed with netarsudil dimesylate. Consequently, the preservative-free and long-acting fixed-combination carteolol-netarsudil containing hydroxypropyl methylcellulose (HPMC) as a thickener (FC-CN-TKN) was prepared in a pH about 5.0 solution using an extremely simple one-pot pH-adjusting solubilization strategy, achieving stable co-solubilization of both active pharmaceutical ingredients. The optimized FC-CN-TKN formulation demonstrated excellent physicochemical stability under refrigerated storage conditions. Additionally, FC-CN exerted no influence on the intraocular penetration of each active compound in the pharmacokinetic study, and HPMC-mediated viscosity enhancement significantly prolonged precorneal retention, further improving its residence time and bioavailability. Importantly, once daily, FC-CN-TKN exerted a potent IOP-lowering effect and protective effect on retinal ganglion cells. The innovative FC-CN-TKN was stable, safe, and effective, being a promising glaucoma therapy.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

The effects of netarsudil ophthalmic solution on the expression of genes involved in fibrogenesis in orbital fibroblasts of patients with thyroid eye disease

Article

Author: Heydari, Mojtaba ; Khademi, Behzad ; Sanie-Jahromi, Fatemeh ; Armaghanifard, Vahid ; Attar, Alireza

BACKGROUND:

Thyroid eye disease (TED) is an autoimmune orbital disorder characterized by fibroblast activation, myofibroblast differentiation, and excessive extracellular matrix production. RhoA/ROCK signaling is increasingly implicated in these fibrotic processes. This study aimed to investigate the effects of the Rho-associated protein kinase (ROCK) inhibitor netarsudil on the expression of fibrogenesis-related genes in orbital fibroblasts derived from patients with TED.

METHODS AND RESULTS:

Primary orbital fibroblasts were isolated from two patients with TED. Cells were treated with varying concentrations of netarsudil (ranging from 2 × 10^- 2 to 2 × 10^- 8 mg/mL). Gene expression of fibrogenesis markers, including TGF-β, α-SMA, ZEB1, Snail, Thy-1, and β-catenin, was assessed via quantitative real-time PCR. Our results demonstrated that netarsudil treatment at non-cytotoxic concentrations not only did not significantly suppress the mRNA expression of the examined fibrogenic markers, but also upregulated the expression of TGF-β, α-SMA, and ZEB1. Higher concentrations of netarsudil appeared to reduce cell viability, suggesting that apparent antifibrotic effects at elevated doses may be secondary to cytotoxicity rather than pathway-specific transcriptional repression.

CONCLUSIONS:

Our findings suggest that non-cytotoxic dose of netarsudil, is insufficient to reverse the constitutively pro-fibrotic transcriptional program in TED orbital fibroblasts. The lack of direct antifibrotic efficacy highlights the complexity of TED fibrogenesis and suggests that redundant or parallel signaling pathways may limit the impact of isolated ROCK inhibition. Further research is required to evaluate combination therapies or alternative targets in TED-related fibrosis.

13 Oct 2026·CIRCULATION

METTL7B Mitigates Hypertension and Vascular Remodeling

Article

Author: Yang, Qiaoxi ; Zhang, Haizeng ; Geng, Bin ; Chen, Zhenzhen ; Dong, Xilan ; Yue, Fengkai ; Ling, Qianhui ; Guo, Xinru ; Cui, Jiarui ; Fan, Luyun ; Tang, Yan ; Cai, Jun

BACKGROUND::

Hypertension is a major risk factor for cardiovascular diseases. RNA N6-methyladenosine (m 6 A) modification is closely linked to hypertension pathogenesis, but key m 6 A-related factors that regulate blood pressure remain unclear. This study aims to identify these regulators and evaluate their therapeutic potential.

METHODS::

We assessed RNA m 6 A changes and METTL (methyltransferase-like) expression in hypertensive aortas via methylated RNA immunoprecipitation sequencing and RNA sequencing (RNA-seq). Global Mettl7b knockout mice and vascular smooth muscle cell (VSMC)–specific Mettl7b knockin and knockout mice were used to evaluate its in vivo role. Downstream target genes were identified via methylated RNA immunoprecipitation sequencing, enhanced cross-linking and immunoprecipitation sequencing, and RNA-seq. METTL7B activators were screened using molecular docking and surface plasmon resonance and validated in vivo via intraperitoneal injection.

RESULTS::

Under hypertensive stress, METTL7B expression positively correlated with global RNA m 6 A content, exhibiting concurrent depletion in VSMCs. In vitro biochemical assays revealed that recombinant METTL7B significantly increased RNA m 6 A levels. Crucially, METTL7B overexpression in METTL3 knockout cells robustly upregulated m 6 A levels, definitively establishing METTL7B as a novel, METTL3-independent RNA m 6 A methyltransferase. Physiologically, VSMC-specific Mettl7b ablation exacerbated angiotensin II–induced hypertensive pathogenesis, structural arterial remodeling, and vascular tone, whereas its overexpression exerted potent vasoprotective effects. Mechanistically, METTL7B recruited HNRNPH1 to catalyze m 6 A deposition at the 3′ untranslated region of FILIP1L mRNA, facilitating its maturation. Importantly, the expression of FILIP1L was positively correlated with blood pressure reduction in humans and mice. Elevated FILIP1L downregulated the expression of its binding protein FLNA (Filamin A), reducing F-actin polymerization, attenuating VSMC contractility, and ultimately lowering blood pressure. Furthermore, FILIP1L overexpression reversed the detrimental effects of Mettl7b knockout on hypertension and vascular remodeling, whereas these effects were not rescued by the mutation of FILIP1L’s m 6 A site. Elucidating the upstream pathology, we found that stress-induced KLF4 directly bound the METTL7B promoter, transcriptionally repressing its expression. Finally, the Food and Drug Administration–approved drug netarsudil exerted preventive and therapeutic effects on hypertension and vascular remodeling by activating METTL7B; notably, these therapeutic benefits were completely abolished in VSMC-specific Mettl7b knockout mice.

CONCLUSIONS::

Collectively, our study identifies a novel RNA m 6 A methyltransferase, METTL7B. The METTL7B-HNRNPH1-FILIP1L axis mitigates hypertension by regulating VSMC dedifferentiation and vascular tone. Targeted activation of METTL7B may emerge as a promising strategy for hypertension.

News (Medical) associated with Netarsudil Mesylate

10 Jul 2026

·allsci.com

Bausch + Lomb’s glaucoma neuroprotective candidate fails Phase II primary endpoint

Bausch + Lomb’s BL1107 glaucoma Phase II trial failed to replicate earlier visual function signals in primary open-angle glaucoma, a setback that closes the topical eye drop program but leaves the company’s broader neuroprotective ambitions intact through a pivot to a sustained-release implant for geographic atrophy. The Phase II study (NCT07168902) enrolled 159 adults with primary open-angle glaucoma or ocular hypertension in a randomized, double-masked, three-arm, parallel-group design comparing BL1107 against timolol maleate 0.5%. The primary endpoint — change from baseline in visual field mean deviation at Day 28 — was not met, and key secondary endpoints assessing visual function, including low-luminance best-corrected visual acuity responder rates, were also not achieved. One secondary endpoint was met: a reduction in intraocular pressure at Day 28, which the company described as evidence of ocular target engagement. No quantitative data were disclosed. The safety profile was consistent with prior BL1107 clinical experience, with no new safety signals identified. The trial was designed to confirm visual function improvements observed in a smaller Phase I/IIa study following 28 days of topical administration. The Phase II enrolled 159 patients, and the data represent a complete topline readout rather than an interim analysis. No efficacy data by treatment arm were reported, and the company did not disclose individual dose levels for BL1107 across the three study arms. Bausch + Lomb (NYSE/TSX: BLCO acquired Whitecap Biosciences in 2025 primarily to develop BL1107 — originally designated WB007 — as a sustained-release implant for geographic atrophy, a late-stage complication of age-related macular degeneration that causes progressive central vision loss. The glaucoma neuroprotection program was pursued in parallel as a secondary strategic objective. Following the Phase II failure, the company said it will discontinue the topical eye drop program entirely and focus on the GA implant, with clinical trials anticipated to begin in 2028 in collaboration with Ripple Therapeutics, whose polymer-free controlled-release technology underpins the delivery platform. BL1107’s mechanism of action has not been fully disclosed publicly, though the asset is characterized as a small molecule with alpha-2 adrenergic agonist properties, a class with established IOP-lowering and proposed neuroprotective effects in glaucoma. BL1107’s failure to replicate even a directional visual field signal at Day 28 in a large, adequately powered cohort raises questions about whether the earlier Phase I/IIa findings reflected a true treatment effect or were subject to small-sample variability. For IOP reduction specifically, netarsudil 0.02% (Rhopressa), a Rho kinase inhibitor, achieved non-inferior IOP lowering to twice-daily timolol in the pivotal ROCKET program, illustrating the competitive standard BL1107 faced on that secondary measure. Cross-trial comparisons are limited by differences in study design, duration, and patient populations. The outcome is consistent with a broader pattern in glaucoma neuroprotection research, where preclinical and small-study signals have repeatedly failed to translate into statistically significant visual field benefits in larger trials. The field has yet to produce an approved neuroprotective agent, and BL1107’s Phase II result does not alter that landscape. Bausch + Lomb’s decision to discontinue the topical program while preserving the sustained-release implant reflects a calculation that the GA opportunity — a larger and less crowded indication — justifies continued investment in the molecule through a different delivery format, even absent confirmatory glaucoma efficacy data. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 2Clinical ResultAcquisition

09 Apr 2025

·www.businesswire.com

Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment career, Dr. Cunningham has led or co-led financings that contributed to the FDA approval of ten therapeutics, including ophthalmic treatments such as Xiidra®, Rhopressa®, Rocklatan®, Syfovre®, and Izervay®. He previously served as Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, where he played a leadership role in the development of Macugen® (pegaptanib sodium), the first VEGF-A inhibitor approved for neovascular age-related macular degeneration and diabetic macular edema. Prior to Eyetech, Dr. Cunningham held clinical development and licensing roles at Pfizer, focused on central nervous system and ophthalmology assets. “Emmett’s extensive background in science, medicine, and strategic investing, particularly within ophthalmology, adds significant depth to our Board at a time of meaningful momentum for Aviceda,” said Jeffrey Nau, Ph.D., M.M.S., President and Chief Executive Officer of Aviceda Therapeutics. “His unique combination of clinical insight, biopharma operating experience, and investment leadership will be instrumental as we advance AVD-104 into pivotal trials for geographic atrophy and continue to build a leading immunology platform.” “Aviceda is advancing a scientifically compelling approach to immunomodulation that directly addresses longstanding challenges in ophthalmology,” said Dr. Cunningham. “The potential of the HALOS™ platform, beginning with AVD-104, extends beyond current treatment paradigms. I look forward to contributing to the company’s efforts to translate their innovative approaches into meaningful outcomes for patients with serious, underserved diseases.” Dr. Cunningham currently serves on the Boards of Eyconis, Oryon Cell Therapies, Nacuity Pharmaceuticals, and InflammX Therapeutics, and has held board positions at more than a dozen innovative biopharma companies, including Annexon Biosciences (NASDAQ: ANNX), GrayBug Vision (NASDAQ: GRAY), Lumos Pharma (NASDAQ: LUMO), SARcode Biosciences (acquired by Shire), Galera Therapeutics (GRTX) and the SFJ Pharmaceutical Group. He is also the founder and former chairman of the Ophthalmology Innovation Summit (OIS), a long-standing platform that brings together leaders in ophthalmic science, innovation, and investment. Dr. Cunningham is an internationally recognized expert in ocular inflammatory and infectious disease, with more than 400 co-authored publications. He earned an M.D. and M.P.H. in epidemiology and statistics from Johns Hopkins University, and a Ph.D. in neuroscience from the University of California at San Diego for research conducted at The Salk Institute. He completed his ophthalmology residency and fellowship training at UCSF and The Francis I. Proctor Foundation, with additional fellowships in Retina at Moorfields Eye Hospital in London and Public health Ophthalmology at The Dana Center of the Wilmer Eye Institute in Baltimore. He currently teaches at California Pacific Medical Center, serves as an Adjunct Clinical Professor of Ophthalmology at Stanford University, and is a Research Associate at UCSF School of Medicine. About Aviceda Therapeutics and AVD-104 Aviceda is a private, clinical-stage biotechnology company located in Cambridge, MA, with a proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform and a clinical-stage ophthalmic candidate, AVD-104, for the treatment of geographic atrophy secondary to age-related macular degeneration. AVD-104 is an intravitreal glycan-coated nanoparticle with a dual mechanism of action that modulates critical inflammatory cellular and complement pathways through 1) direct deactivation of inflammatory microglia/macrophages’ phagocytic activity and repolarization of these activated microglia/macrophages to their healing state and 2) inhibition of complement cascade amplification. Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including immunology, fibrosis, oncology, and neurology. Visit the company website to learn more about Aviceda Therapeutics and follow the company on LinkedIn and X (formerly Twitter).

Executive ChangeDrug Approval

06 Feb 2024

·www.biospace.com

Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

February 6, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced presentations on NCX 470 and NCX 1728 at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024, a key ophthalmology conference which will be held from May 5 to May 9, 2024 in Seattle, WA, United States. Abstract/Presentation Title: Tolerability and intraocular pressure (IOP)-lowering efficacy following 5-day repeated dosing with NCX 470 0.1% ophthalmic solution, Lumigan® and Rhopressa®: a comparative head-to-head study in rabbits and dogs Type: Poster Session Session Title: Tools and advancements in glaucoma diagnosis, monitoring, medications, and lasers Date: May 6, 2024 from 8:30 am to 10:15 am (U.S. local time) Presenter: Francesco Impagnatiello, PhD, Nicox Research Institute NCX 470, a novel NO-donating bimatoprost eye drop, is currently in Phase 3 clinical development for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the two Phase 3 clinical trials, have been announced in October 2022. The second Phase 3 clinical trial, Denali, is currently ongoing, and the results are expected in 2025, based on current recruitment rates. Abstract/Presentation Title: NCX 1728, a novel nitric oxide (NO)-donating avanafil: Formulation development and in vivo testing in a rabbit model of ischemia/reperfusion injury of the optic nerve head and retina Type: Poster Session Session Title: Neuroprotection, blood flow, ischemia-reperfusion and aqueous humor dynamics Date: May 5, 2024 from 3:15 pm to 5:00 pm (U.S. local time) Presenter: Corinna Galli, PhD, Nicox Research Institute NCX 1728 is an NO-donating phosphodiesterase-5 (PDE5) inhibitor, the lead compound in a new class of NO-donating molecules based entirely on NO-mediated activity. NCX 1728 is currently under preclinical evaluation for development in retinal conditions. Nicox Corporate Status Update The Company estimates it is financed until June 2024, based exclusively on the development of NCX 470. The Company is pursuing licensing and other business development discussions, exploring multiple strategic options and is also discussing with its creditors to restructure its debt. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information . Analyst coverage Bryan, Garnier & Co Eric Yoo Paris, France H.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts Nicox Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development T +33 (0)4 97 24 53 00 communications@nicox.com Forward-Looking Statements The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 2.7 of the “Rapport Annuel 2022” and in section 4 of the “Rapport semestriel financier et d’activité 2023” which are available on Nicox’s website ( ). Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 Attachment EN_ARVO 2024_ABSTRACTS_ 20240206_F

Phase 3License out/in

100 Deals associated with Netarsudil Mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
D11031	Netarsudil Mesylate	S01EX05	DB13931

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Santen Pharmaceutical Co., Ltd.	19 Jun 2026
Glaucoma, Open-Angle	United States	Alcon Laboratories, Inc.	18 Dec 2017
Ocular Hypertension	United States	Alcon Laboratories, Inc.	18 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Corneal Edema	Phase 3	United States	Price Vision Group	05 Aug 2019
Fuchs' Endothelial Dystrophy	Phase 3	United States	Price Vision Group	22 Jul 2019
Ocular Hypotension	Phase 2	United States	Aerie Pharmaceuticals, Inc.	20 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2026	Not Applicable	Glaucoma	42	Netarsudil as adjunctive therapy (Exfoliative Glaucoma)	mkhdiyrqgt(uawbignrcp) = conjunctival hyperemia (20 patients 47.6%), allergic conjunctivitis (4 patients, 9.5%), and superficial punctate keratitis (3 patient, 7.1%). upledzocsa (nhdwarggfd )	Positive	03 May 2026
ARVO2026	Not Applicable	Glaucoma, Open-Angle	235	Netarsudil (primary open-angle glaucoma (OAG))	ieuodhtzjm(jzxmrdaukq) = nmbfmtsdbn djxhlfycaq (apagvictvl, 3.9) View more	Positive	03 May 2026
				Netarsudil (combined mechanism glaucoma (CMG))	ieuodhtzjm(jzxmrdaukq) = bpxsxzirjm djxhlfycaq (apagvictvl, 4.1) View more
ARVO2026	Not Applicable	Glaucoma, Open-Angle	40	bimatoprost	fmwkvjgfmz(cafwjwdrpc) = pcposshyzp lguhiasvph (onrynaeycx ) View more	Negative	03 May 2026
ARVO2026	Not Applicable	VEGF \| CFTR	439	Netarsudil	apwpnravxv(rgstrwgptb) = pcmgvpmkpv cqfwishjkk (mofzszexgj )	Positive	03 May 2026
				Ranibizumab	apwpnravxv(rgstrwgptb) = siiagvvgku cqfwishjkk (mofzszexgj )
APAO2024	Not Applicable	Glaucoma	-	Netarsudil eyedrops	ekoimqwswb(pjuqrvxuev) = Adverse events were reported in 8% of patients, with the most common being conjunctival hyperemia (4%) and ocular discomfort (2%) obbvnvrcdu (zowvtyiivd )	-	22 Feb 2024
NCT04620135 (J-ROCKET, CTgov)	Phase 3	Glaucoma, Open-Angle	245	Netarsudil ophthalmic solution 0.02% (Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle)	ykovwloccj(bascvwrhld) = brgdqtdlra kfkxjrjukr (xxajixoguy, 0.157) View more	-	27 Feb 2023
				Ripasudil hydrochloride hydrate ophthalmic solution 0.4% (Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%)	ykovwloccj(bascvwrhld) = koquwtmexo kfkxjrjukr (xxajixoguy, 0.155) View more
NCT03971357 (CTgov)	Phase 2/3	Fuchs' Endothelial Dystrophy	19	Netarsudil (Netarsudil)	tkoyrmbbsx(yfwlmcotuo) = zgjukhtnzq kdzsxkreos (gpxnrktklu, 45) View more	-	06 Feb 2023
				Placebo (Placebo)	tkoyrmbbsx(yfwlmcotuo) = mhdsjpniga kdzsxkreos (gpxnrktklu, 49) View more
NCT04498169 (Pubmed) Manual	Phase 2	Corneal Edema \| Fuchs' Endothelial Dystrophy	40	Netarsudil (QD)	jfbxdexsio(ylmxhlqcae) = lnekllkhep rsfkrwnivu (xfshhzqksi, 7.99) View more	Positive	03 Nov 2022
				Netarsudil (BID)	jfbxdexsio(ylmxhlqcae) = lxvslidblj rsfkrwnivu (xfshhzqksi, 8.75) View more
NCT04498169 (Fuchs, CTgov)	Phase 2	Corneal Edema \| Fuchs' Endothelial Dystrophy	40	Netarsudil Ophthalmic (Once Daily Netarsudil Ophthalmic Solution)	oouqwvaygb(fhfkcspslc) = bfycfpfgqe fjbbrflfyp (zouihjwxiu, 35.72) View more	-	01 Sep 2022
				Netarsudil Ophthalmic (Twice Daily Netarsudil Ophthalmic Solution)	oouqwvaygb(fhfkcspslc) = hrrxerdbiu fjbbrflfyp (zouihjwxiu, 39.12) View more
AAO2021	Not Applicable	Glaucoma	29	Netarsudil	bhhgfxynee(zudsblnvpa) = ecmfddxhvz hsgxmchvxe (fyflnrwbjq, 4.80)	Positive	13 Nov 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis